Dopaminergic

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

Retrieved on: 
Monday, March 11, 2024

CARSON CITY, Nev., March 11, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that its recently completed funding round provides opportunity to further the Company’s clinical priorities in Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and ascites/liver disease. The Company continues to explore longevity and aging in conjunction with external collaborators. 

Key Points: 
  • The Company continues to explore longevity and aging in conjunction with external collaborators.
  • The trial targets enrolling 100-150 patients in a 6-month trial with the Part 3 (motor) score on the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the primary endpoint.
  • Only one Phase 3 trial is potentially needed as BIV201 has already received Orphan and Fast Track designations.
  • BIV201 remains our most de-risked program, but it unfortunately is a program that will take two years to complete.

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

Retrieved on: 
Tuesday, March 5, 2024

bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).
  • Under the terms of the collaboration agreement, both wild type human cells and physiologically relevant disease model cells can be generated through individual project agreements.
  • “We are thrilled to partner with bit.bio and to leverage the company’s unique platform for the generation of human cells.

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson’s Disease with its NLRP3 Inhibitor, Dapansutrile

Retrieved on: 
Tuesday, February 20, 2024

Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease.

Key Points: 
  • Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease.
  • Parkinson’s is a complex neurodegenerative disease, which as reported by Cure Parkinson’s, is the fastest growing neurological condition in the world.
  • Treatment with dapansutrile has the potential to arrest this cyclical process of cell damage thereby slowing the progression of the disease.
  • The trial will seek to enroll 36 participants with early Parkinson’s disease.

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192

Retrieved on: 
Thursday, October 12, 2023

The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of both single and multiple doses of orally administered HL192 in healthy participants.

Key Points: 
  • The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of both single and multiple doses of orally administered HL192 in healthy participants.
  • KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals marked a major milestone by dosing the first human healthy participant in their Phase 1 clinical trial, assessing HL192 (NurrOn designation code: ATH-399A) which is being developed for the treatment of Parkinson's disease (PD).
  • HanAll Biopharma, in collaboration with Daewoong Pharmaceutical, solidified a co-development partnership with NurrOn Pharmaceuticals to leverage the therapeutic potential of HL192 across various neurodegenerative diseases.
  • The initial results from the Phase 1 clinical trial of HL192 are expected in the second half of 2024.

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

Retrieved on: 
Monday, August 28, 2023

BETHESDA, Md., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced preclinical data demonstrating the Company’s lead drug candidate GT-02287 significantly decreased Parkinson’s disease (PD)-associated pathology and improved motor dysfunction in two different preclinical models of Parkinson’s disease. Of note, GT-02287 significantly reduced plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration, in a mouse model of GBA1-PD. The findings are being presented in two posters, including one that was accepted as a late breaking abstract, at the International Congress of Parkinson's Disease and Movement Disorders® being held in Copenhagen, Denmark from August 27-31, 2023.

Key Points: 
  • Of note, GT-02287 significantly reduced plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration, in a mouse model of GBA1-PD.
  • Researchers used a mouse model of GBA1-PD, created using conduritol beta epoxide (CBE) to induce GCase deficit comparable to GBA1-PD.
  • Data from the poster describes the effect of GT-02287 on rotenone-induced neurotoxic effects in a PD animal model.
  • “Buoyed by these encouraging data, we look forward to initiating the Phase 1 clinical study with GT-02287 and advancing the development of this potentially best-in-class treatment for GBA1 Parkinson’s disease.”

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Retrieved on: 
Tuesday, April 25, 2023

BOTHELL, Wash., April 25, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of new data from its small molecule programs enhancing the HGF/MET neurotrophic system. The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass. and virtually.

Key Points: 
  • The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass.
  • “These and other data presented at this year’s AAN Annual Meeting further support other previously reported post hoc findings from ACT-AD that showed improvements in plasma biomarkers and measures of cognition.
  • Additionally, we reported new data that further elucidate the interaction between fosgonimeton and AChEIs.
  • The information presented in this press release is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Retrieved on: 
Thursday, November 10, 2022

BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the third quarter ended September 30, 2022, and highlighted recent corporate progress.

Key Points: 
  • The latest preclinical data provide further validation of the potential utility of our approach and mechanism of action of GT-02287.
  • If these results are supported in our upcoming clinical trials, we believe that GT-02287 could become a potential first-in-class disease-modifying therapy for Parkinsons disease.
  • Presented new preclinical data for GT-02287, Gains lead compound for Parkinsons Disease at the International Congress of Parkinsons Disease and Movement Disorders 2022 Annual Meeting.
  • Cash, cash equivalents and marketable securities were $25.7 million as of September 30, 2022 compared to $36.8 million at December 31, 2021.

Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons

Retrieved on: 
Monday, September 26, 2022

BETHESDA, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for the treatment of Parkinson’s Disease.

Key Points: 
  • Study results were presented at the Shaare Zedek Medical Center GBA Parkinsons disease symposium by Manolo Bellotto, Ph.D., Chief Strategy Officer & General Manager for Gain Therapeutics, in a presentation entitled, Non-inhibitory Chaperones for GBA-Parkinsons Disease.
  • The study was conducted using human induced pluripotent stem cells (iPSC) derived from donor patients with GBA-associated Parkinsons disease, which were then differentiated into dopaminergic neurons.
  • We are especially excited by these latest data because they were generated in a model that replicates Parkinsons disease in patient-derived cells, commented Matthias Alder, Chief Executive Officer of Gain Therapeutics.
  • Mutations in the GBA1 gene, encoding the lysosomal enzyme GCase, represents the most common genetic risk factor for Parkinsons disease (PD).

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease

Retrieved on: 
Monday, September 19, 2022

BETHESDA, Md., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced the presentation of new preclinical data at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain, evaluating the neuroprotective effect of Gain’s lead ‘Structurally Targeted Allosteric Regulator’ (STAR) compound, GT-02287, in preclinical in vitro and in vivo models of Parkinson’s disease.

Key Points: 
  • We are especially excited by these latest data which expand on the accumulating preclinical evidence supporting the potential disease-modifying properties of our novel small molecule candidate, GT-02287, said Joanne Taylor, Ph.D., Senior Vice President of Research at Gain Therapeutics.
  • If these results are supported in future clinical studies, GT-02287 could become an important first-in-class disease-modifying therapy for Parkinsons disease.
  • In the first study, the ability of GT-02287 to neutralize CBE-mediated neurodegeneration was evaluated in rat mesencephalic neurons.
  • Mutations in the GBA1 gene, encoding the lysosomal enzyme GCase, represents the most common genetic risk factor for Parkinsons disease (PD).

Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease

Retrieved on: 
Monday, April 11, 2022

As of today, there are many medications for treating symptoms, however none that change the course of the disease.

Key Points: 
  • As of today, there are many medications for treating symptoms, however none that change the course of the disease.
  • Annovis is developing Buntanetap, a translational inhibitor of neurotoxic aggregating proteins (TINAPs), for the treatment of early and late Parkinson's.
  • Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and other chronic neurodegenerative diseases, including Alzheimer's in Down Syndrome (AD-DS).
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .